Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients
Investigating the Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients: A Pilot, Randomized Double-blinded, Sham-controlled Trial
The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:
- Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
- Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.
Participants will:
- Receive acupuncture treatment twice per week for 6 weeks.
- Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
- Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Linda LD Zhong, PhD
- Telefonnummer: +65 67911744
- E-mail: linda.zhong@ntu.edu.sg
Undersøgelse Kontakt Backup
- Navn: Huangyan Chen
- Telefonnummer: +65 97663672
- E-mail: huangyan001@e.ntu.edu.sg
Studiesteder
-
-
-
Singapore, Singapore, S637551
- Nanyang Technological University, School of Biological Sciences
-
Kontakt:
- Huangyan Chen
- Telefonnummer: +65 97663672
- E-mail: huangyan001@e.ntu.edu.sg
-
Kontakt:
- Linda LD Zhong, PhD
- Telefonnummer: +65 65921733
- E-mail: linda.zhong@ntu.edu.sg
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults aged 21 to 75 years at the time of consent;
- Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
- No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
- GERD-Q score ≥8 (indicating active GERD symptoms);
- Ability and willingness to provide written informed consent to participate.
Exclusion Criteria:
-
Structural or organic gastrointestinal disease, including but not limited to:
- gastrointestinal malignancy,
- eosinophilic esophagitis,
- esophageal stricture, varices, or infections,
- active peptic ulcer disease,
- gastric or duodenal tumors;
-
Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);
-
History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;
-
Use of prohibited medical treatment:
- acupuncture treatment on the abdomen and chest within past 1 month,
- concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
- antibiotics, prebiotics, probiotics, or immunosuppressants within 1 month prior to screening;
-
Presence of an implanted cardiac pacemaker;
-
History of hypersensitivity to acupuncture, or needle phobia;
-
Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;
-
Pregnant or breastfeeding;
-
Current participation in other clinical trials that could interfere with study outcomes.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Electroacupuncture (EA)
The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
|
Sham-komparator: Sham-electroacupuncture (SEA)
The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention. |
The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
≥ 50% reduction in total GERD-Q score or normalization (<8) |
From enrollment to the end of follow-up at 16 weeks
|
|
Gastrointestinal Symptom Rating scale (GSRS)
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point decrease in mean GSRS Reflux domain value |
From enrollment to the end of follow-up at 16 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
≥ 0.5 point improvement on the mean QOLRAD score |
From enrollment to the end of follow-up at 16 weeks
|
|
Euro QoL (EQ-5D-5L)
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
change in index utility |
From enrollment to the end of follow-up at 16 weeks
|
|
Hospital Anxiety and Depression Scale (HADS)
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
categorical shift from ≥ 11 to < 11 or ≥ 8 to < 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale |
From enrollment to the end of follow-up at 16 weeks
|
|
Visceral Sensitivity Index (VSI)
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
≥ 15% reduction from baseline |
From enrollment to the end of follow-up at 16 weeks
|
|
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
Tidsramme: At baseline
|
At baseline
|
|
|
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100% |
From enrollment to the end of follow-up at 16 weeks
|
|
Bang's blinding index (BBI)
Tidsramme: End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
James' blinding index (JBI)
Tidsramme: End of first week and sixth week of intervention
|
End of first week and sixth week of intervention
|
|
|
Patient's global impression of change (PGIC)
Tidsramme: From mid-treatment to the end of follow-up at 16 week
|
From mid-treatment to the end of follow-up at 16 week
|
|
|
Daily patient diary
Tidsramme: From enrollment to the end of follow-up at 16 weeks
|
From enrollment to the end of follow-up at 16 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Linda LD Zhong, PhD, Nanyang Technological University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- IRB-2025-1138
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD sharing will be available upon request.
IPD-delingstidsramme
Data will become available within 7 years after completion of the clinical trial.
IPD-delingsadgangskriterier
Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .